FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920941143> ?p ?o ?g. }

• W2920941143 endingPage "508" @default.
• W2920941143 startingPage "502" @default.
• W2920941143 abstract "•HeFH and CHL phenotype are common among patients with premature MI. •Among patients with early MI, HeFH has more atheromatous burden than CHL phenotype. •CHL phenotype is associated with more intense inflammation than HeFH. •There is significant overlapping in the clinical diagnosis of HeFH and CHL phenotype. Background Heterozygous familial hypercholesterolemia (HeFH) and combined hyperlipidemia (CHL) phenotype are associated with premature myocardial infarction (MI). Objective To assess the prevalence of HeFH and CHL phenotype among young survivors of MI and compare patients’ characteristics with these 2 lipid disorders. Methods We recruited 382 young survivors of MI (≤40 years). Fasting lipids, lipoprotein(a) [Lp(a)], apolipoprotein A-1, and apolipoprotein B (apoB) levels were determined. Using the Dutch Lipid Clinic Network (DLCN) algorithm, patients having definite or probable HeFH were identified. Patients with apoB levels >120 mg/dL and triglyceride levels >170 mg/dL (1.92 mmol/L) [>90th percentile of 326 age and sex-matched healthy controls] were classified as having CHL phenotype. Common carotid artery intima-media thickness (CCA-IMT) was measured by B-mode ultrasonography. Results Eighty-one patients (21.2%) had definite/probable HeFH and 62 (16.2%) had CHL phenotype. Twenty-three patients fulfilled the criteria for both HeFH and CHL phenotype and were removed from further comparisons. Patients with HeFH (n = 58) had higher levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, Lp(a), and apoB, whereas patients with CHL phenotype (n = 39) had higher levels of triglycerides and lower high-density lipoprotein (HDL)-cholesterol levels. The prevalence of metabolic syndrome was higher in patients with CHL phenotype compared to those with HeFH (67.0% vs 16.4%, P < .001). Patients with HeFH had more extensive coronary artery disease (3-vessel disease: 36.2% vs 12.8%, P = .011) and greater right CCA-IMT (0.67 ± 0.11 mm vs 0.56 ± 0.09 mm, P < .001) and left CCA-IMT (0.68 ± 0.10 mm vs 0.56 ± 0.08 mm, P < .001) compared to CHL phenotype patients. Conclusions Both HeFH and CHL phenotype are common among patients with premature MI. CHL phenotype compared to HeFH is associated with less atheromatous burden in coronary and carotid arteries at the time of first MI. Heterozygous familial hypercholesterolemia (HeFH) and combined hyperlipidemia (CHL) phenotype are associated with premature myocardial infarction (MI). To assess the prevalence of HeFH and CHL phenotype among young survivors of MI and compare patients’ characteristics with these 2 lipid disorders. We recruited 382 young survivors of MI (≤40 years). Fasting lipids, lipoprotein(a) [Lp(a)], apolipoprotein A-1, and apolipoprotein B (apoB) levels were determined. Using the Dutch Lipid Clinic Network (DLCN) algorithm, patients having definite or probable HeFH were identified. Patients with apoB levels >120 mg/dL and triglyceride levels >170 mg/dL (1.92 mmol/L) [>90th percentile of 326 age and sex-matched healthy controls] were classified as having CHL phenotype. Common carotid artery intima-media thickness (CCA-IMT) was measured by B-mode ultrasonography. Eighty-one patients (21.2%) had definite/probable HeFH and 62 (16.2%) had CHL phenotype. Twenty-three patients fulfilled the criteria for both HeFH and CHL phenotype and were removed from further comparisons. Patients with HeFH (n = 58) had higher levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, Lp(a), and apoB, whereas patients with CHL phenotype (n = 39) had higher levels of triglycerides and lower high-density lipoprotein (HDL)-cholesterol levels. The prevalence of metabolic syndrome was higher in patients with CHL phenotype compared to those with HeFH (67.0% vs 16.4%, P < .001). Patients with HeFH had more extensive coronary artery disease (3-vessel disease: 36.2% vs 12.8%, P = .011) and greater right CCA-IMT (0.67 ± 0.11 mm vs 0.56 ± 0.09 mm, P < .001) and left CCA-IMT (0.68 ± 0.10 mm vs 0.56 ± 0.08 mm, P < .001) compared to CHL phenotype patients. Both HeFH and CHL phenotype are common among patients with premature MI. CHL phenotype compared to HeFH is associated with less atheromatous burden in coronary and carotid arteries at the time of first MI." @default.
• W2920941143 created "2019-03-22" @default.
• W2920941143 creator A5012042837 @default.
• W2920941143 creator A5028746991 @default.
• W2920941143 creator A5035360425 @default.
• W2920941143 creator A5049646201 @default.
• W2920941143 creator A5070529706 @default.
• W2920941143 creator A5085745655 @default.
• W2920941143 date "2019-05-01" @default.
• W2920941143 modified "2023-10-12" @default.
• W2920941143 title "Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden" @default.
• W2920941143 cites W1493319331 @default.
• W2920941143 cites W1691844256 @default.
• W2920941143 cites W1934027766 @default.
• W2920941143 cites W1973178110 @default.
• W2920941143 cites W1980550449 @default.
• W2920941143 cites W1982752532 @default.
• W2920941143 cites W1985081697 @default.
• W2920941143 cites W1985269443 @default.
• W2920941143 cites W1991165792 @default.
• W2920941143 cites W2010412420 @default.
• W2920941143 cites W2029561034 @default.
• W2920941143 cites W2033879310 @default.
• W2920941143 cites W2037104620 @default.
• W2920941143 cites W2042489459 @default.
• W2920941143 cites W2050838276 @default.
• W2920941143 cites W2052858141 @default.
• W2920941143 cites W2057170733 @default.
• W2920941143 cites W2057334971 @default.
• W2920941143 cites W2073609009 @default.
• W2920941143 cites W2092649782 @default.
• W2920941143 cites W2097754892 @default.
• W2920941143 cites W2103714496 @default.
• W2920941143 cites W2114837151 @default.
• W2920941143 cites W2142802148 @default.
• W2920941143 cites W2154157771 @default.
• W2920941143 cites W2297027011 @default.
• W2920941143 cites W2512338755 @default.
• W2920941143 cites W2684890128 @default.
• W2920941143 cites W2750646243 @default.
• W2920941143 cites W2766824918 @default.
• W2920941143 cites W2805722352 @default.
• W2920941143 doi "https://doi.org/10.1016/j.jacl.2019.02.007" @default.
• W2920941143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30956097" @default.
• W2920941143 hasPublicationYear "2019" @default.
• W2920941143 type Work @default.
• W2920941143 sameAs 2920941143 @default.
• W2920941143 citedByCount "13" @default.
• W2920941143 countsByYear W29209411432019 @default.
• W2920941143 countsByYear W29209411432020 @default.
• W2920941143 countsByYear W29209411432021 @default.
• W2920941143 countsByYear W29209411432022 @default.
• W2920941143 countsByYear W29209411432023 @default.
• W2920941143 crossrefType "journal-article" @default.
• W2920941143 hasAuthorship W2920941143A5012042837 @default.
• W2920941143 hasAuthorship W2920941143A5028746991 @default.
• W2920941143 hasAuthorship W2920941143A5035360425 @default.
• W2920941143 hasAuthorship W2920941143A5049646201 @default.
• W2920941143 hasAuthorship W2920941143A5070529706 @default.
• W2920941143 hasAuthorship W2920941143A5085745655 @default.
• W2920941143 hasConcept C104317684 @default.
• W2920941143 hasConcept C126322002 @default.
• W2920941143 hasConcept C127716648 @default.
• W2920941143 hasConcept C134018914 @default.
• W2920941143 hasConcept C164705383 @default.
• W2920941143 hasConcept C2776104379 @default.
• W2920941143 hasConcept C2778163477 @default.
• W2920941143 hasConcept C2779091943 @default.
• W2920941143 hasConcept C2779120738 @default.
• W2920941143 hasConcept C2779134260 @default.
• W2920941143 hasConcept C2780072125 @default.
• W2920941143 hasConcept C500558357 @default.
• W2920941143 hasConcept C54355233 @default.
• W2920941143 hasConcept C555293320 @default.
• W2920941143 hasConcept C57089818 @default.
• W2920941143 hasConcept C62746215 @default.
• W2920941143 hasConcept C71924100 @default.
• W2920941143 hasConcept C86803240 @default.
• W2920941143 hasConcept C90924648 @default.
• W2920941143 hasConceptScore W2920941143C104317684 @default.
• W2920941143 hasConceptScore W2920941143C126322002 @default.
• W2920941143 hasConceptScore W2920941143C127716648 @default.
• W2920941143 hasConceptScore W2920941143C134018914 @default.
• W2920941143 hasConceptScore W2920941143C164705383 @default.
• W2920941143 hasConceptScore W2920941143C2776104379 @default.
• W2920941143 hasConceptScore W2920941143C2778163477 @default.
• W2920941143 hasConceptScore W2920941143C2779091943 @default.
• W2920941143 hasConceptScore W2920941143C2779120738 @default.
• W2920941143 hasConceptScore W2920941143C2779134260 @default.
• W2920941143 hasConceptScore W2920941143C2780072125 @default.
• W2920941143 hasConceptScore W2920941143C500558357 @default.
• W2920941143 hasConceptScore W2920941143C54355233 @default.
• W2920941143 hasConceptScore W2920941143C555293320 @default.
• W2920941143 hasConceptScore W2920941143C57089818 @default.
• W2920941143 hasConceptScore W2920941143C62746215 @default.
• W2920941143 hasConceptScore W2920941143C71924100 @default.
• W2920941143 hasConceptScore W2920941143C86803240 @default.
• W2920941143 hasConceptScore W2920941143C90924648 @default.

• next